When AI designs a drug, who gets the credit?
Unresolved AI inventorship rules in major jurisdictions may shape how Australian agencies approach AI-assisted R&D procurement and IP ownership clauses.
Key points
- US patent office now treats AI as a mere tool, reversing Biden-era guidance requiring disclosure of AI's role in inventions.
- AI-generated drug discoveries raise unresolved questions about inventorship, IP protection, and innovation incentives globally.
- Limited direct APS relevance; the IP and patentability questions are primarily for Australian IP Australia and legal policy teams.
Implications for Australian agencies
- Monitor IP Australia and DISR policy teams may want to monitor how the US and other jurisdictions resolve AI inventorship questions, as Australian patent law could face similar pressure.
- Consider Agencies commissioning AI-assisted research or innovation may want to consider whether existing IP ownership and attribution clauses in contracts adequately address AI-generated outputs.
Implications are AI-generated. Starting points, not advice — see methodology for how they're framed.
View original source
Copied.
"When AI designs a drug, who gets the credit?"
Source: MIT Technology Review – AI
Published: 21 August 2026
URL: https://www.technologyreview.com/2026/08/21/1142627/when-ai-designs-a-drug-who-gets-the-credit/
MIT Technology Review examines the emerging legal tension around AI-generated pharmaceutical discoveries and who qualifies as an inventor. Under the current Trump administration, the US Patent and Trademark Office treats AI as a tool equivalent to a calculator, requiring no disclosure. This reverses Biden-era guidance and leaves open significant questions about whether excluding AI-generated outputs from IP protection could chill investment in AI-driven drug development. Drug companies are currently keeping humans in the loop and documenting their involvement to preserve patentability, but practitioners acknowledge this is a holding position pending future legal clarification.
Implications for Australian agencies:
- [Monitor] IP Australia and DISR policy teams may want to monitor how the US and other jurisdictions resolve AI inventorship questions, as Australian patent law could face similar pressure.
- [Consider] Agencies commissioning AI-assisted research or innovation may want to consider whether existing IP ownership and attribution clauses in contracts adequately address AI-generated outputs.
Retrieved from SIMS, 16 September 2026.